15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Milestone Pharmaceuticals Inc, 4 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $3.00 to $8.00 (about 2.7x), a sign of real disagreement on valuation. The average target of $6.50 sits 475% above the current $1.13. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 3 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.23 next quarter toward $-0.77 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Strong Buy
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Milestone Pharmaceuticals Inc.
As of Sep, 4 of 4 firms rate MIST a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
MIST EPS & revenue forecast
EPS · NEXT QUARTER
$-0.23
Range $-0.27 – $-0.20 · 5 analysts · +51% YoY
Next period, 5 analysts expect Milestone Pharmaceuticals Inc to earn $-0.23 a share (range $-0.27 – $-0.20), versus $-0.15 a year earlier. Full-year consensus is $-0.84, growing to $-0.77 the year after.
REVENUE · NEXT QUARTER
$2.0M
Range $1.1M – $3.0M · 5 analysts · +27% YoY
Revenue is expected to reach $2.0M (range $1.1M – $3.0M), +26.6% year-over-year. Full-year consensus is $3.8M, rising to $22.1M next year.
Top analysts covering Milestone Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MIST.
#1
BF
Brandon Folkes
HC Wainwright & Co. · Rank #221
Buy
$8.00+608.0% to target
Overall win rate
42%
+ Follow
#2
Patrick R. Trucchio
HC Wainwright & Co. · Rank #230
Buy
$10.00+785.0% to target
Overall win rate
36%
+ Follow
#3
Edward Tenthoff
Piper Sandler · Rank #337
Buy
$7.00+519.5% to target
Overall win rate
29%
+ Follow
#4
Mohit Bansal
Wells Fargo
Buy
$7.00+519.5% to target
Coverage
—
+ Follow
#5
OB
Olivia Brayer Saunders
Cantor Fitzgerald
Buy
$3.00+165.5% to target
Coverage
—
+ Follow
MIST stock forecast FAQ
What is MIST's average 12-month price target?+
The 4 analysts with a live target average $6.50 for Milestone Pharmaceuticals Inc over the next 12 months, ranging from a $8.00 high to a $3.00 low.
Is MIST stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 4 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for MIST?+
The Street-high target is $8.00 (HC Wainwright & Co.), and the Street-low is $3.00 (Cantor Fitzgerald). The average of all 4 active targets is $6.50.
How many Wall Street analysts cover MIST?+
4 analysts have an active rating on Milestone Pharmaceuticals Inc, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering MIST?+
Among analysts who currently cover MIST, Brandon Folkes of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #221). Their current call is Buy with a $8.00 target.
What is Milestone Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.23 per share (range $-0.27 – $-0.20) across 5 analysts. Full-year EPS is projected at $-0.84, rising to $-0.77 the following year.
How much revenue is Milestone Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $2.0M (range $1.1M – $3.0M). Full-year revenue is projected at $3.8M, growing to $22.1M next year.
Have analysts been upgrading or downgrading MIST lately?+
As of Sep, 4 of 4 firms rate MIST a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MIST calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
